Enabling the future of cell and gene therapy with innovative solutions
Driving your CGT pipeline forward from concept to commercial success
With over 30 years of leadership in cell and gene therapy (CGT), we have learned one thing: every therapy is unique. That is why our end-to-end CGT solutions are built for flexibility, while enabling both compliance and speed.
Whether you are advancing into clinical development or preparing for commercial launch, we deliver automated workflows, high-quality reagents and stem cells to genetically engineered cell products, our scalable platform for manufacturing and QC is designed to de-risk development, compress timelines, and avoid costly detours, so you can focus on what matters most: advancing your therapy faster.
We are trusted by pharma leaders
We bring decades of experience, proven technology, a global presence, and a commitment to quality and speed.
7/8
Approved engineered T cell therapies* are manufactured using Miltenyi Biotec's solutions
350+
Active clinical trials worldwide** are carried out using CliniMACS® Instruments
400+
Custom programmed applications created with assistance of Miltenyi Biotec's experts
* Approved cell therapies and gene-modified cell therapies in EU and USA, excluding minimally manipulated cell therapies, cord blood products, and tissue-engineered therapies.
** Active clinical trials, hospital treatments, or commercial treatments using CliniMACS Instruments for manufacturing of cell products.